A prospective, multicenter, multinational study examines how fractional flow reserve (FFR) can impact treatment plans and outcomes in patients with stable coronary artery disease (CAD) or acute coronary syndrome (ACS). Results showed more than one-third of the patients’ initial treatment plans changed after FFR. The findings from the global registry were presented as late-breaking clinical research at the Society for Cardiovascular Angiography and Interventions (SCAI) 2019 Scientific Sessions, May 19-22 in Las Vegas.

Quantum Genomics announced the enrollment of the first patient in its QUORUM Phase IIb study of its lead clinical candidate, firibastat, in patients with heart failure after acute myocardial infarction (AMI). Firibastat is a first-in-class brain aminopeptidase A inhibitor, being developed for the treatment of resistant hypertension and heart failure.

June 14, 2019 – An expert consensus statement provides recommendations for optimizing the financial operations of the ...

Silk Road Medical Inc. announced the presentation of real-world data for the treatment of patients with carotid artery disease at risk for stroke at the Society for Vascular Surgery 2019 Vascular Annual Meeting (VAM), June 12-15 in National Harbor, Md. In a headline presentation, Mahmoud Malas, M.D., of the University of California, San Diego School of Medicine shared updated results for the ongoing TransCarotid Artery Revascularization (TCAR) Surveillance Project.

Orchestra BioMed Inc. announced it has formed a global strategic partnership with Terumo Corp. for development and commercialization of the Virtue Sirolimus-Eluting Balloon (SEB), one of Orchestra’s lead assets, in the percutaneous coronary and peripheral interventions field.

Boston Scientific Corp. has initiated the OPTION trial to compare safety and effectiveness of the next-generation Watchman FLX left atrial appendage closure (LAAC) platform to first-line oral anticoagulants (OAC) for stroke risk reduction in patients with non-valvular atrial fibrillation (AF) who undergo a cardiac ablation procedure. OACs used in the trial will include direct oral anticoagulants (DOAC) and warfarin.

In a letter sent to healthcare providers, the U.S. Food and Drug Administration (FDA) validates that Abiomed’s Impella RP heart pump is safe and effective for treatment of right heart failure. The letter comes after the FDA examined the results from Abiomed’s 18-month post-approval study (PAS) of 42 Impella RP patients. The data shows a 64 percent survival rate and 90 percent heart recovery for the subgroup of PAS patients who met the enrollment criteria of Impella RP’s premarket clinical studies. That survival rate is, as the FDA writes in its letter, “similar to the premarket clinical study survival rate,” which was 73 percent.